ACTolog in Patients With Solid Cancers (ACTolog)

February 3, 2025 updated by: Immatics US, Inc.

Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers

The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) and the main biomarkers screening. If the patient is eligible, white blood cells will be collected with a leukapheresis for the manufacture of the IMA101 product.

MANUFACTURE: IMA101 product will be made from the patient's white blood cells.

TREATMENT: IMA101 product will be administered to the patient intravenously after lymphodepleting pre-conditioning with chemotherapy (fludarabine and cyclophosphamide).

Low-dose IL-2 will be self-administered twice daily for a total of 28 doses after infusion of IMA101 product. In Cohort 2, atezolizumab will be administered every 3 weeks, starting no earlier than 3 weeks after the IMA101 product infusion and after hematologic recovery.

Patients will be monitored closely throughout the study.

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • University of Texas MD Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patients must have pathologically confirmed advanced/metastatic cancer prior to enrollment.
  2. HLA phenotype positive.
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  4. Life expectancy > 6 months prior to enrollment.
  5. Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog).
  6. The patient has adequate organ and marrow function per protocol
  7. At least one lesion (metastasis or primary tumor) being considered accessible by non-high-risk collection procedures for biopsy.
  8. The patient has adequate hepatic function per protocol
  9. The patient has serum creatinine clearance ≥50 mL/min by the Cockcroft-Gault formula.
  10. The patient has adequate pulmonary function per protocol
  11. Acceptable coagulation status
  12. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  13. Male subjects must agree to use effective contraception or abstinence while on study and for 90 days after infusion of the ACTolog T-cell product.
  14. Ability of subject to understand and the willingness to sign written informed consent for study participation.
  15. Confirmed availability of production capacities for the patient's ACTolog products.
  16. ACTolog target expression as evaluated by the in vitro diagnostic device IMA_Detect: Patient's tumor must express at least one ACTolog target as assessed by quantitative PCR (qPCR) (to be assessed from a tumor biopsy to be performed if all other eligibility criteria are met).

Exclusion Criteria

  1. Any condition contraindicating leukapheresis.
  2. Patients with brain metastases. Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis.
  3. HIV infection, active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue. If positive test results are not indicative of an active infection, patients can be included.
  4. Treatment with excluded therapy per protocol
  5. Previous extensive radiotherapy to the lung or liver during the last 4 months prior to lymphodepletion regimen.
  6. The patient has cardiac conditions defined per protocol
  7. Patients with prior stem cell transplantation or solid organ transplantation.
  8. The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
  9. Active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation.
  10. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years.
  11. The patient is pregnant or is breastfeeding.
  12. Serious autoimmune disease per protocol
  13. History of hypersensitivity to cyclophosphamide, fludarabine or IL-2.
  14. Immunosuppression, not related to prior treatment for malignancy.
  15. History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.
  16. Patients with Grade 3 or higher immune-related toxicities related to prior checkpoint inhibitors

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: IMA101 product only (Cohort 1)
  • Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
  • Infusion of the IMA101 T-cell product(s)
  • Post-infusion administration of low-dose recombinant human interleukin-2
Drug: Fludarabine
Fludarabine infusion
Other Names:
  • Fludarabine monophosphate
Drug: Cyclophosphamide
Cyclophosphamide infusion
Other Names:
  • Cytoxan
Biological: IMA101 product
i.v. infusion of IMA101 product(s).
Biological: Recombinant human interleukin-2
Low dose IL-2 Infusion for two weeks
Other Names:
  • Proleukin
  • Aldesleukin
Diagnostic test: IMADetect
IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
Experimental: IMA101 product + atezolizumab (Cohort 2)
  • Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
  • Infusion of the IMA101 T-cell product(s)
  • Post-infusion administration of low-dose recombinant human interleukin-2
  • Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
Drug: Fludarabine
Fludarabine infusion
Other Names:
  • Fludarabine monophosphate
Drug: Cyclophosphamide
Cyclophosphamide infusion
Other Names:
  • Cytoxan
Biological: IMA101 product
i.v. infusion of IMA101 product(s).
Biological: Recombinant human interleukin-2
Low dose IL-2 Infusion for two weeks
Other Names:
  • Proleukin
  • Aldesleukin
Diagnostic test: IMADetect
IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
Drug: Atezolizumab
Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
Other Names:
  • Tecentriq

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of adverse events (Safety and tolerability) of IMA101 alone or in combination with atezolizumab
Time Frame: up to 18 months
up to 18 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Peripheral T-cell persistence (assessment of frequency of T-cells over time)
Time Frame: up to 18 months
up to 18 months
Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)
Time Frame: up to 18 months
up to 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Immatics US, Inc.

Collaborators

M.D. Anderson Cancer Center

Investigators

  • Study Director: Cedrik Britten, M.D., Immatics US, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2017

Primary Completion (Actual)

September 22, 2021

Study Completion (Actual)

September 22, 2021

Study Registration Dates

First Submitted

August 8, 2016

First Submitted That Met QC Criteria

August 18, 2016

First Posted (Estimated)

August 23, 2016

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 3, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IMA101-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Fludarabine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe